NSCLC & Skin Health: Improving Quality of Life
Proactive skin care dramatically improves the quality of life for patients battling non-small cell lung cancer (NSCLC). The COCOON trial demonstrates that enhanced dermatologic management significantly diminishes skin issues, common side effects of treatments like amivantamab and lazertinib.Researchers found that using a regimen including oral doxycycline, clindamycin lotion, and ceramide-based moisturizer, alongside educational digital tools, lead to fewer severe adverse events related to rash, skin conditions, and nail infections compared to standard care. News Directory 3 is following this pioneering research. Discover what’s next for NSCLC patients seeking better skin health during cancer treatment.
COCOON Trial Shows Promise for NSCLC Skin Side Effects
an enhanced approach to dermatologic management significantly decreased the occurrence of grade 2 or higher dermatologic adverse events in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC). these findings come from the phase 2 COCOON trial,which will be presented at the 2025 ASCO Annual Meeting in Chicago.
The study investigated the combination of enhanced dermatologic management (COCOON DM) with amivantamab (Rybrevant) and lazertinib (Lazcluze) compared to standard of care dermatologic management (SoC DM). Skin and nail changes are common with cancer therapies, especially targeted treatments like amivantamab and lazertinib, impacting a patient’s quality of life. Current treatments frequently enough react to these side effects, but proactive strategies may offer better results.
The COCOON trial randomized 138 patients with locally advanced or metastatic EGFR-mutated NSCLC to either COCOON DM (n = 70) or SoC DM (n = 68). The COCOON DM group received a regimen including oral doxycycline or minocycline, clindamycin lotion, chlorhexidine wash, and ceramide-based moisturizer. A digital tool aided adherence with reminders and education.
Patient-reported outcomes, gathered biweekly, assessed dermatologic symptoms and thier impact on quality of life. The Skindex-16 questionnaire and Patient’s Global Impression of Severity (PGI-S) scale were used to evaluate these factors over the first 12 weeks of treatment.
Results showed that by week 12, the COCOON DM group experienced less severe dermatologic adverse events and a better quality of life compared to the SoC DM group. At cycle 3, day 15, the average Skindex total score was significantly lower in the COCOON DM arm (P = .02).
More patients in the COCOON DM group reported mild or no symptoms for rash,skin condition,and nail infection. Notably, the percentage of patients reporting no symptoms for rash (21% vs 7%; P = .04) and skin condition (23% vs 7%; P = .02) significantly increased with COCOON DM at cycle 3 day 15. Nail infection symptoms also showed numerical improvement (27% vs 16%; P = .13).
These interim data suggest that COCOON DM offers a superior approach to reducing dermatologic adverse event severity,warranting further study and potential integration into clinical practice for managing skin side effects during NSCLC treatment with amivantamab and lazertinib.
What’s next
Further research will explore the long-term benefits of enhanced dermatologic management and its impact on overall treatment outcomes for patients with EGFR-mutated NSCLC.